Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | KCNK3 | O14649 | 6/20 | 0.81 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721612 | 0.90 | MAPT (0.73) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL4429130 | 0.88 | MAPT (0.71) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL3949532 | 0.88 | KMT2A (0.78) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL5390989 | 0.88 | MAPT (0.71) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL30739719 | 0.88 | MAPT (0.71) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL5229927 | 0.87 | KCNK3 (0.68) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL4429129 | 0.87 | MAPT (0.69) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL6778054 | 0.87 | SMN1; SMN2 (0.78) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL5842541 | 0.87 | KCNK3 (0.68) | KMT2AKCNK3KCNK9MAPTRAB9A | |
| SCHEMBL678394 | 0.87 | MAPT (0.69) | KMT2AKCNK3KCNK9MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-118043327-A | FGFR inhibitors and methods of use thereof | 思康睿奇(上海)药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4022391-A2 | HEAT SENSITIVE RECORDING MATERIAL WITH NON-PHENOLIC COLOR DEVELOPERS | Solenis Technologies Cayman, L.P. (KY) | 2022-07-06 | — | — | EP | disclosed |
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2021-12-23 | — | — | US | disclosed |
| WO-2021041600-A2 | HEAT SENSITIVE RECORDING MATERIAL WITH NON-PHENOLIC COLOR DEVELOPERS | SOLENIS TECHNOLOGIES CAYMAN, L.P. (KY) | 2021-03-04 | — | — | WO | disclosed |
| CN-110483423-A | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO | 2019-11-22 | — | — | CN | disclosed |
| CN-108863959-A | P2X4 RECEPTOR ANTAGONIST | 日本化学药品株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447027-B2 | Treating long QT syndrome | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| CN-105669491-A | Acidylation method of amine | 苏州大学 | 2016-06-15 | — | — | CN | disclosed |
| US-20060142587-A1 | Benzoisothiazolone compositions | L'OREAL (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1655290-A1 | Compositions comprising a benzoisothiazolone derivative and their use in the cosmetic field | L'OREAL (FR) | 2006-05-10 | — | — | EP | disclosed |
| EP-1534657-A1 | PROCESS FOR PREPARING ALDEHYDE COMPOUNDS | INVISTA Technologies S.à.r.l. (US) | 2005-06-01 | — | — | EP | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| WO-2004020381-A1 | PROCESS FOR PREPARING ALDEHYDE COMPOUNDS | INVISTA TECHNOLOGIES S.À.R.L. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6664427-B1 | From an unsaturated compound by hydroformylation and in the presence of a catalyst system comprising a Group VIII metal and a bidentate phosphorus ligand having two trivalent phosphorus atoms bound to salicylanilide groups | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-16 | — | — | US | disclosed |
| WO-2001093642-A1 | PHOSPHORESCENT ORGANIC LIGHT EMITTING DEVICES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-1994022417-A1 | AN ORAL HYGIENE PRETREATMENT COMPOSITION | SMITHKLINE BEECHAM PLC (GB) | 1994-10-13 | — | — | WO | disclosed |
| EP-0127876-A2 | Process for preparing phosphonic-acid esters, and phosphonic acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-12-12 | — | — | EP | disclosed |
| US-4342875-A | STABILIZERS FOR OLEFIN POLYMERS | CINCINNATI-MILACRON, INC. (US) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142587-A1 | Benzoisothiazolone compositions | COL1A1, TYR, CUTA | KMT2A 3462/4885KCNK3 836/4885KCNK9 1769/4885 |
| US-20210395210-A1 | INHIBITION OF BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSP90AB1, HSP90AB2P | KMT2A 4500/4885KCNK3 4338/4885KCNK9 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.